Growth is structural, but not equal.

Strong set of revenues in Q1 but the stock is overvalued.

Guidance upgrade thanks to weight loss pill.

Prelim Q1 numbers c 15% below expectations.

End of talks with Jindal is only slightly negative.

Potential game changer with the disposal of nuclear fleet.